Tate & Lyle Acquires CP KELCO for $1.8 Billion to Strengthen Plant-Based Portfolio
Tate & Lyle, a British sweetener manufacturer, announced the acquisition of US-based CP Kelco for $1.8 billion. This strategic move is intended to boost Tate & Lyle's specialty ingredients business to meet the growing demand for plant-based products.
The acquisition transaction includes $1.15 billion in cash and the issuance of 75 million new Tate & Lyle shares to CP Kelco's parent company, JM Huber Corporation. The transaction will make JM Huber the largest shareholder of Tate with a 16% stake and the right to appoint two non-executive directors to Tate's board of directors. CP Kelco, known for its pectin, specialty gum and other natural ingredients, has recently faced declining sales and margin pressures, sparking investor concerns. The proposed transaction is expected to generate at least $50 million in cost benefits by the end of the second fiscal year after completion.
The acquisition is in line with Tate & Lyle's strategy to meet growing consumer demand for sustainable plant-based products and fewer artificial additives. Chief Executive Officer Nick Hampton stressed that the deal would help the company meet the growing market for sustainable ingredients.Despite the strategic fit, Tate & Lyle’s shares fell more than 8%, reflecting investor concerns about CP Kelco’s recent performance.
2026-08-04
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Reducing to Refocus: Novo Nordisk’s 9,000-Job Cut and the Strategic Realignment in Pharma
-
The Cost of 2,000 Jobs: How ExxonMobil Uses Layoffs to Announce a Global Chemical Map Reshuffle
-
Evonik and AMSilk Expand Collaboration to Develop Sustainable Biotech Silk Materials
-
Biochem to Acquire BASF’s Global Glycinates Business
-
DyStar Becomes a Wholly-Owned Subsidiary of Zhejiang Longsheng Group, Ending Longstanding Shareholder Disputes with a $5 Billion Deal
-
Iran Conflict Leaves a Long Shadow on Drug Supply
-
AstraZeneca India Eyes ₹3,400 Crore Bengaluru Sale
-
Sinopec and Saudi Aramco Launch $10 Billion Joint Venture, Accelerating Gulei Refining and Petrochemical Phase II Project
-
Sun Pharma’s Organon Bid Would Redraw Indian Pharma M&A
-
McKinsey Pays to Close a Purdue Liability Chapter
Recommend Reading
-
China National Salt Industry Corporation Advances 10,000 t/y Sodium Metal Expansion Project, Industry Leader Invests Nearly RMB 100 Million
-
When BASF Lets Agriculture Fly Solo: A Capital Repricing of Scale and Ambition
-
Novo Nordisk Enters High-Stakes Bidding War with Pfizer for Metsera
-
Breakup! Vland Biotech and Evonik Part Ways as GHS Joint Venture Falls Short of Expectations
-
Pfizer Seen Holding Strategic Edge in Bidding Battle for Metsera
-
Weak Decline in TDI Market in September
-
FSANZ Moves Toward Approval of Insect-Resistant Corn COR121
-
Thymol Gel Wins EPA Approval for Beekeepers
-
Premium Global Chemical Sourcing Requests (27-31 Oct 2025)
-
September Pure Benzene Market Overview (September 1–30, 2025)